Patents by Inventor Martin Maiden

Martin Maiden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130089571
    Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.
    Type: Application
    Filed: October 24, 2012
    Publication date: April 11, 2013
    Inventors: Martin Maiden, Ian Feavers, Andrew Pollard
  • Patent number: 8318179
    Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunization comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: November 27, 2012
    Assignee: ISIS Innovation, Ltd.
    Inventors: Martin Maiden, Ian Feavers, Andrew Pollard
  • Publication number: 20100183676
    Abstract: The present invention relates to a composition comprising at least one purified Opa HV 1 protein epitope and at least one purified Opa HV2 protein epitope. The epitopes are preferably purified protein epitopes, preferably recombinant epitopes. The composition is preferably a pharmaceutical composition, more preferably a vaccine composition. The invention also relates to methods of immunisation and to specific formulations presented in the tables, and to novel nucleic acids encoding Opa alleles.
    Type: Application
    Filed: December 22, 2005
    Publication date: July 22, 2010
    Applicant: ISIS INNOVATION LTD.
    Inventors: Martin Maiden, Ian Feavers, Andrew Pollard
  • Publication number: 20070224222
    Abstract: The present invention relates to compositions comprising at least one purified PorA protein antigen and at least one purified FetA protein antigen. In particular, said PorA/FetA antigens are antigenically variable antigens comprising the variable regions of PorA/FetA. Specific combinations of PorA/FetA epitopes are presented for example in Table 3. The invention also relates to methods of immunisation comprising administering said compositions, and to methods for producing compositions. Preferably the compositions are purified protein compositions. Preferably the compositions are vaccine compositions.
    Type: Application
    Filed: June 3, 2005
    Publication date: September 27, 2007
    Inventors: Martin Maiden, Ian Feavers, Andrew Pollard